HKSE - Delayed Quote HKD

CSPC PHARMA (1093.HK)

4.460

-0.030

(-0.67%)

At close: January 28 at 12:08:04 PM GMT+8

CSPC Pharmaceutical Group And 2 Other Penny Stocks To Watch This Year

Global markets have shown resilience, with major U.S. stock indexes rebounding and European stocks rising sharply amidst easing inflation concerns, while Japan's markets faced a downturn due to potential interest rate hikes. In such a fluctuating economic landscape, identifying stocks with solid financial foundations becomes crucial for investors seeking growth opportunities. Penny stocks, although an older term, remain relevant as they often represent smaller or newer companies that can...

Simply Wall St. 11 days ago

CHJTF

CSPCY

CYYHF
CSPC Pharmaceutical Group And 2 Other Promising Penny Stocks To Watch

As global markets navigate a landscape marked by rate cuts from the ECB and SNB, and anticipation of a Federal Reserve decision, investors are keenly observing how these shifts influence various sectors. Penny stocks, often associated with smaller or newer companies, continue to offer intriguing opportunities for growth at lower price points. Despite being considered somewhat outdated as a term, these stocks can still provide value when they exhibit strong financial health and solid...

Simply Wall St. last month

CHJTF

CSPCY

BIP.SI
AstraZeneca Inks Agreement to Boost Cardiovascular Pipeline

AZN inks an agreement with CSPC Pharmaceutical to develop a novel lipid-lowering therapy targeting various cardiovascular diseases.

Zacks 3 months ago

AZN

CSPCY
AstraZeneca Inks $1.92B License Pact With Hong Kong-Based Firm To Boost Cardiovascular Pipeline

On Monday, AstraZeneca plc (NASDAQ:AZN) entered into an exclusive license agreement with Hong Kong-based CSPC Pharmaceutical Group Ltd to advance the development of an early-stage, novel small-molecule lipoprotein (a) (Lp(a)) disruptor that has the potential to offer additional benefits for patients with dyslipidemia. Dyslipidemia is a metabolic disorder that occurs when there are abnormal levels of lipids or fats, such as cholesterol and triglycerides, in the blood. Under the terms of the agree

Benzinga 3 months ago

AZN

CSPCY
FOCUS-China's drugmakers can't sell mRNA shots but haven't quit yet

China's vaccine developers stuck with unused mRNA COVID shots and idle manufacturing plants are pursuing new targets for the novel messenger RNA technology, but they face a tough path, crimped by a lack of revenue. Three Chinese companies - Walvax Biotechnology, CSPC Pharmaceutical Group and Stemirna Therapeutics - came up with mRNA vaccines that won limited emergency approvals in Asia. However, Walvax and CSPC are not currently manufacturing three of their China market shots, a China health official told Reuters.

Reuters 9 months ago

CSPCY

MRNA

300142.SZ

Performance Overview

Return	1093.HK	HANG SENG INDEX
YTD	-6.11%	+0.92%
1-Year	-21.93%	+26.79%
3-Year	-44.99%	-15.05%

News

Life

Entertainment

Finance

Sports

New on Yahoo

Yahoo Finance

CSPC PHARMA (1093.HK)

CSPC Pharmaceutical Group And 2 Other Penny Stocks To Watch This Year

CSPC Pharmaceutical Group And 2 Other Promising Penny Stocks To Watch

AstraZeneca Inks Agreement to Boost Cardiovascular Pipeline

AstraZeneca Inks $1.92B License Pact With Hong Kong-Based Firm To Boost Cardiovascular Pipeline

FOCUS-China's drugmakers can't sell mRNA shots but haven't quit yet

Performance Overview